There has been much variation between epidemiological studies that report the prevalence of ankylosing spondylitis (AS). This study aimed to analyze the diagnostic prevalence rates and treatment patterns of male and female AS patients in the United States adult insured population from 2006 to 2016. Trends in AS prevalence were calculated for the 11-year period covering January 1, 2006 to December 31, 2016. Adult (18+ years old) AS patients were included in this retrospective analysis of medical and pharmacy claims data from the IBM Marketscan Commercial, Medicaid and Medicare-Supplemental Claims database. Prevalence was determined as having ≥1 AS diagnostic codes (ICD-9:720.0; ICD-10:M45.x). Trends in treatment patterns were also analyzed and stratified by gender. The AS prevalence increased from 0.04 to 0.09% from 2006 to 2016. The mean age between 2006 and 2016 ranged from 49.52–50.00 years. In 2006, approximately 40% of AS patients were female, while in 2016 over 47% of AS patients were female. Rates of use of TNF inhibitors and oral glucocorticoids increased, while NSAIDs and non-biologic DMARDs (sulfasalazine & methotrexate) rates decreased. Opioid use rates were stable. In 2016, males were more likely to be prescribed biologics, while females were more likely to be prescribed methotrexate, sulfasalazine, NSAIDs, muscle relaxants, anticonvulsants, opioids, and glucocorticoids. The prevalence of AS diagnosis codes more than doubled between 2006 and 2016, but the very low prevalence suggests that AS continues to be underdiagnosed and under-addressed in routine clinical practice. Despite the increase in female AS patients, females were less likely to be prescribed biologics compared to male AS patients.

中文翻译：

---

2006-2016 年美国男性和女性强直性脊柱炎患者的诊断流行率和治疗模式趋势

报告强直性脊柱炎 (AS) 患病率的流行病学研究之间存在很大差异。本研究旨在分析 2006 年至 2016 年美国成年保险人群中男性和女性 AS 患者的诊断患病率和治疗模式。计算了 2006 年 1 月 1 日至 12 月 31 日的 11 年期间的 AS 患病率趋势, 2016. 成人（18 岁以上）AS 患者被纳入对 IBM Marketscan Commercial、Medicaid 和 Medicare-Supplemental Claims 数据库的医疗和药房索赔数据的回顾性分析。患病率被确定为具有 ≥1 个 AS 诊断代码 (ICD-9:720.0; ICD-10:M45.x)。治疗模式的趋势也按性别进行了分析和分层。从 2006 年到 2016 年，AS 患病率从 0.04% 增加到 0.09%。2006 年至 2016 年的平均年龄范围为 49.52-50.00 岁。2006 年，大约 40% 的 AS 患者为女性，而 2016 年超过 47% 的 AS 患者为女性。TNF 抑制剂和口服糖皮质激素的使用率增加，而 NSAID 和非生物 DMARD（柳氮磺胺吡啶和甲氨蝶呤）的使用率下降。阿片类药物使用率稳定。2016 年，男性更有可能服用生物制剂，而女性更有可能服用甲氨蝶呤、柳氮磺胺吡啶、非甾体抗炎药、肌肉松弛剂、抗惊厥药、阿片类药物和糖皮质激素。在 2006 年至 2016 年期间，AS 诊断代码的流行率增加了一倍以上，但极低的流行率表明，在常规临床实践中，AS 仍然未被充分诊断和解决。尽管女性 AS 患者有所增加，